Physician profile
Edward Bernaski
NPI 1063485803
$68,769.18
in general payments reported to CMS, 2019-2025
12 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $14K · 2021: $243 · 2022: $28.16 · 2023: $226 · 2024: $57.22 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $475 · Food and Beverage: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $475.00 |
| Food and Beverage | $300.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $40,602.95 | 2019-2023 | Varithena Administration Pack |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22,819.67 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $4,212.51 | 2019-2020 | |
| Chiesi USA, INC. | $475.00 | 2025 | Elfabrio |
| Glaxosmithkline, LLC. | $167.20 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $161.17 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.57 | 2021-2023 | Lifevest |
| Alnylam Pharmaceuticals INC. | $115.99 | 2019 | |
| Tactile Systems Technology INC | $37.12 | 2022-2023 | Flexitouch Plus, Entre Plus |
| E.R. Squibb & Sons, L.L.C. | $25.62 | 2021-2024 | Eliquis |
| Lexicon Pharmaceuticals, INC. | $21.72 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Bernaski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.